Cargando…

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

A formulation of aflibercept for intravitreal injection (Eylea) is approved for the treatment of patients with exudative age-related macular degeneration (AMD). Aflibercept has a significantly higher affinity for Vascular endothelial growth factor (VEGF)-A compared with other monoclonal anti-VEGF an...

Descripción completa

Detalles Bibliográficos
Autores principales:	García-Layana, Alfredo, Figueroa, Marta S., Araiz, Javier, Ruiz-Moreno, José M., Gómez-Ulla, Francisco, Arias-Barquet, Luis, Reiter, Nicholas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4607716/ https://www.ncbi.nlm.nih.gov/pubmed/26442858 http://dx.doi.org/10.1007/s40266-015-0300-y

Ejemplares similares

Early and intermediate age-related macular degeneration: update and clinical review
por: García-Layana, Alfredo, et al.
Publicado: (2017)

Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration
por: García-Layana, Alfredo, et al.
Publicado: (2015)

A Review of Current Management of Vitreomacular Traction and Macular Hole
por: García-Layana, Alfredo, et al.
Publicado: (2015)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021)

Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration
por: Barthelmes, Daniel, et al.
Publicado: (2016)

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
por: Koike, Naoko, et al.
Publicado: (2019)

Management of Wet Age-Related Macular Degeneration in Spain: Challenges for Treat and Extend Implementation in Routine Clinical Practice
por: García-Layana, A., et al.
Publicado: (2019)

A Delphi Study to Detect Deficiencies and Propose Actions in Real Life Treatment of Neovascular Age-Related Macular Degeneration
por: García-Layana, Alfredo, et al.
Publicado: (2014)

Intravitreal sirolimus with adjunct aflibercept versus aflibercept monotherapy for persistent, exudative age-related macular degeneration: a pilot study
por: Rowe, Lucas W., et al.
Publicado: (2023)

CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
por: de Oliveira Dias, João Rafael, et al.
Publicado: (2017)

Do Nutritional Supplements Have a Role in Age Macular Degeneration Prevention?
por: Pinazo-Durán, Maria D., et al.
Publicado: (2014)

AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE–RELATED MACULAR DEGENERATION: The ARI2 Study
por: Blanco-Garavito, Rocio, et al.
Publicado: (2018)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014)

Efficacy and Safety of an Aflibercept Treat-and-Extend Regimen in Treatment-Naïve Patients with Macular Oedema Secondary to Central Retinal Vein Occlusion (CRVO): A Prospective 12-Month, Single-Arm, Multicentre Trial
por: Garcia-Arumi, Jose, et al.
Publicado: (2018)

Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab
por: Narayan, Daniel Sanju, et al.
Publicado: (2015)

Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration
por: Kikushima, Wataru, et al.
Publicado: (2017)

Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity
por: Kikushima, Wataru, et al.
Publicado: (2021)

Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice
por: Plaza-Ramos, Pablo, et al.
Publicado: (2019)

Combined treatment of exudative age related macular degeneration with photodynamic therapy and intravitreal triamcinolone
por: Ruiz-Moreno, José Mª, et al.
Publicado: (2008)

One-year outcomes of fixed treatment of intravitreal aflibercept for exudative age-related macular degeneration and the factor of visual prognosis
por: Ono, Aoi, et al.
Publicado: (2018)

Aflibercept for the Treatment of Age-Related Macular Degeneration
por: Trichonas, George, et al.
Publicado: (2013)

Challenges in Diabetic Macular Edema Management: An Expert Consensus Report
por: Udaondo, Patricia, et al.
Publicado: (2021)

Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study
por: Sakamoto, Shinichi, et al.
Publicado: (2018)

Ziv-aflibercept and bevacizumab for exudative age-related macular degeneration: A retrospective comparison of clinical outcomes and cost at 1 year
por: Singh, Sumit Randhir, et al.
Publicado: (2020)

Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial)
por: Wykoff, Charles C, et al.
Publicado: (2014)

Association between Polygenic Risk Score and One-Year Outcomes Following As-Needed Aflibercept Therapy for Exudative Age-Related Macular Degeneration
por: Shijo, Taiyo, et al.
Publicado: (2020)

A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result
por: Kikushima, Wataru, et al.
Publicado: (2023)

Smoking and Age-Related Macular Degeneration: Review and Update
por: Velilla, Sara, et al.
Publicado: (2013)

Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept
por: Stewart, Michael W
Publicado: (2012)

Therapeutic Modalities of Exudative Age-related Macular Degeneration
por: Mavija, Milka, et al.
Publicado: (2014)

Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
por: Ali Said, Yasmin, et al.
Publicado: (2022)

Combination of Aflibercept and Bromfenac Therapy in Age-Related Macular Degeneration: A Pilot Study Aflibercept and Bromfenac in AMD
por: Wyględowska-Promieńska, Dorota, et al.
Publicado: (2015)

The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
por: Musiał-Kopiejka, Magdalena, et al.
Publicado: (2022)

Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B, et al.
Publicado: (2022)

Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration
por: Tamiya, Ryosuke, et al.
Publicado: (2023)

Early Signs of Exudative Age-Related Macular Degeneration in Asians
por: Sasaki, Mariko, et al.
Publicado: (2014)

Unusual visual loss in a patient with exudative macular degeneration
por: Peng, Enoch T., et al.
Publicado: (2022)

Macular Hole Surgery in the Case of Wet Age-Related Macular Degeneration Treated with Intravitreal Aflibercept
por: Nowosielska, Agnieszka
Publicado: (2019)

Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept
por: Sato, Tomohito, et al.
Publicado: (2021)

Optical Coherence Tomography-Based Deep-Learning Models for Classifying Normal and Age-Related Macular Degeneration and Exudative and Non-Exudative Age-Related Macular Degeneration Changes
por: Motozawa, Naohiro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ct4msf1njbsis5o3h6tvndtcp4